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Abstract 
Mitochondria are damaged by cardiac ischemia-reperfusion (I/R) injury 
but can contribute to cardioprotection. We tested if hyperkalemic cardioplegia 
(CP) and lidocaine (LID) differently modulate mitochondrial (m) bioenergetics 
and protect hearts against I/R injury. Guinea pig hearts (n=71) were perfused 
with Krebs Ringer's (KR) solution before perfusion for 1 min just before 
ischemia with either CP (16 mM K+), or LID (1 mM) or KR (control, 4 mM K+). 
The 1 min perfusion period assured treatment during ischemia but not on 
reperfusion. Cardiac function, NADH, FAD, m[Ca2+] and superoxide (ROS) 
were assessed at baseline, during the 1 min perfusion, and continuously 
during I/R. During the brief perfusion before ischemia, CP and LID decreased 
ROS and increased NADH without changing m[Ca2+]. Additionally, CP 
decreased FAD. During ischemia, NADH was higher and ROS was lower after 
CP and LID, whereas m[Ca2+] was lower only after LID. On reperfusion, NADH 
and FAD were more normalized, and m[Ca2+] and ROS remained lower after 
CP and LID. Better functional recovery and smaller infarct size after CP and 
LID were accompanied by better mitochondrial function. These results 
suggest that mitochondria may be implicated, directly or indirectly, in 
protection by CP and LID against I/R injury. 
Keywords: ischemia/reperfusion, lidocaine, mitochondrial calcium load, 
mitochondrial redox potential, potassium cardioplegia, reactive oxygen 
species 
 
Introduction 
Myocardial injury can occur during cardiac surgery, 
cardiopulmonary bypass or drug-induced hypothermic circulatory 
arrest. Although several primary methods of preserving myocardial 
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function have been developed, these techniques are being constantly 
modified and refined to achieve the most optimal post operative 
outcome.1 Potassium depolarization is a fundamental component of 
modern cardioplegia2 solutions and is an important adjunct to 
hypothermia in that it can provide significant added protection if 
ischemia occurs during cardiac surgery. However, there remains 
controversy over what constitutes an optimal hyperkalemic 
cardioplegia (CP) solution, insofar as hyperkalemia, per se, may 
predispose the myocardium to accumulation of intracellular Na+,3 and 
may cause some deleterious effects such as cytosolic Ca2+ uptake.4 
During hyperkalemic arrest the Na+/K+ ATPase pump has been shown 
to be active, which may compromise recovery on reperfusion.5 It was 
postulated that plasma membrane hyperpolarizing agents, such as the 
Na+ channel blocker lidocaine (LID) might have an advantage over 
depolarizing, hyperkalemic solutions by providing a better 
maintenance of cell membrane potential and ion homeostasis.6 Indeed, 
several studies have shown that adding a hyperpolarizing agent to a 
high K+ CP improved function and reduced cellular damage.7-10 
Mitochondria play a key role in ischemia/reperfusion (I/R)-
induced injury. During I/R a decrease in cytosolic pH occurs because of 
anaerobic metabolism; this acidity leads to increased cytosolic Na+ and 
in tandem to increased cytosolic Ca2+. As a result, mitochondrial Ca2+ 
(mCa2+) can rise to a high level, which can lead to abrupt cell death or 
eventually to opening of the mitochondrial permeability transition pore 
(MPTP), which allows released cytochrome c and other factors to 
trigger apoptotic cell death. Mitochondria also play a key role in 
generating reactive O2 species (ROS), not only during reperfusion, but 
also during ischemia; ROS contribute to mitochondrial injury and 
subsequent cell damage.11-13 Therefore, targeting the mitochondrion to 
alleviate I/R injury has engendered much interest in understanding the 
mitochondrial component of cardioprotection. Indeed, we14-16 and 
other investigators17 have shown recently that targeting mitochondrial 
electron transport chain (ETC) complex I protected against I/R injury. 
CP and LID, in addition to their mechanism of action to arrest 
action potential and contractile activity, may also have direct or 
indirect effects at the mitochondrial level. We questioned if CP or LID 
would better preserve mitochondrial bioenergetics and protect against 
myocardial I/R injury by a brief reduction in metabolic activity before 
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ischemia (indirect effect), or by an effect on mitochondrial 
bioenergetics during ischemia (direct effect). To address this we 
investigated effects of both CP and LID on the mitochondrial redox 
state, ROS, and mitochondrial Ca2+ (m[Ca2+]) as each variable was 
measured continuously in intact beating hearts during I/R. We 
hypothesized that CP or LID, given just before ischemia, would 
differentially preserve mitochondrial redox state and decrease ROS 
generation and m[Ca2+] during I/R. To our knowledge, this is the first 
study to compare the effects of these two methods of arresting hearts 
on mitochondrial function measured continuously in isolated perfused 
hearts. 
Materials and Methods 
Langendorff Heart Preparation 
The investigation conformed to the Guide for the Care and Use 
of Laboratory Animals (US National Institutes of Health Publication No. 
85-23, Revised 1996). The Medical College of Wisconsin Biomedical 
Resources Studies Committee approved this study. Guinea pig hearts 
(n=71) were isolated and prepared as previously described in detail.18-
23 Animals were anesthetized with ketamine (50 mg/kg) and heparin 
was administered to prevent clotting. Following decapitation and 
thoracotomy, hearts were removed and perfused at 55 mmHg via the 
aortic root with a Krebs Ringer's solution (KR: in mM 138 Na+, 4.5 K+, 
1.2 Mg2+, 2.5 Ca2+, 134 Cl-, 15 HCO3-, 1.2 H2PO4-, 11.5 glucose, 2 
pyruvate, 16 mannitol, 0.1 probenecid, 0.05 EDTA, and 5 U/L insulin) 
gassed with 3% CO2, 97% O2 (pH 7.4) at 37°C. Pyruvate improves 
performance in guinea pig hearts,24,25 and mannitol, a non-metabolized 
sugar, supports the oncotic pressure of the KR solution. Probenecid 
was added to accentuate loading of fluorescent dyes.26 A saline-filled 
balloon catheter attached to a transducer was used to measure LV 
pressure (LVP). Coronary flow was measured using an ultrasonic 
flowmeter (model T106X; Transonic Systems, Ithaca, NY) placed 
directly into the aortic inflow line as previously described.18-23 
Spontaneous heart rate was monitored with bipolar electrodes placed 
in the right atrial and ventricular walls.27 Cardiac O2 delivery was 
calculated as coronary flow • heart weight−1 • PaO2 • 24 μl O2 / ml 
(37°C) at 760 mmHg, O2 consumption (MVO2) as coronary flow • heart 
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weight−1 • (PaO2 – PvO2) • 24 μl O2 / ml (37°C) at 760 mmHg, and 
cardiac efficiency as developed LVP • heart rate / MVO2. 
Measurements of Cardiac Mitochondrial Redox State, 
O2•- and [Ca2+] 
All fluorescence signals were detected at 103 to 105 photons/s. 
FAD fluorescence is derived only from mitochondria; the majority of 
the NADH signal also arises from mitochondria28-30 The majority of 
superoxide (O2•-) likely originates from cardiac mitochondria with only 
small part derived from non-mitochondrial sources because O2•- 
generation in the isolated heart is very sensitive to mitochondrial 
inhibitors and insensitive to inhibitors of xanthine oxidase.19 It is also 
possible that non-myocyte sources such as endothelial and other 
sources can contribute to the total O2•- generated. For example, the 
mitochondrial content in endothelial cells ranges between 2-5%31 while 
mitochondria comprise 22-37% of the volume of cardiac myocytes.32,33 
These observations lead to the conclusion that most of the O2•- 
generated in ischemic hearts originates in mitochondria of cardiac 
myocytes. Myocardial Ca2+ signals arise from noncytosolic sources 
after quenching by MnCl2;34 the major noncytosolic source is the 
mitochondrial compartment because of its large volume relative to cell 
volume.32,33 
NADH and FAD, m[Ca2+], and ROS production were measured 
near continuously through the LV free wall using one of four excitation 
and emission fluorescence spectra18-23 in different subsets of hearts. A 
trifurcated fiberoptic probe (3.8 mm2/bundle) was placed against the 
LV to excite and record light signals at specific wavelengths using 
spectrophotofluorometers (SLM Instruments Inc, Urbana, IL; or Photon 
Technology International, London, Ontario). Light penetration and its 
fluorescence sensitivity are dependent on the light source intensity and 
wavelength. For Ca2+ the signal is transmural but attenuated at the 
endocardial surface to 20 to 30% of that at the epicardial surface.35 
In a subset of hearts, as described previously,20,21,36 10 μM 
dihydroethidium (DHE), a fluorescent probe used to detect the O2•- 
radical,37-39 was loaded for 20 min and washed out, the LV free wall 
was excited at 540 nm, and light emission was recorded at 590 nm. 
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O2•- non-enzymatically converts DHE to 2-hydroxyethidium (2-OH-E+) 
or a precursor that appears to be rapidly made, is labile, and 
fluoresces at a slightly shorter wavelength than the heme-peroxidase 
oxidation product ethidium that can intercalate to bind with DNA.38,39 
In other hearts NADH autofluorescence was assessed at 350 nm 
excitation and 450 and 390 nm emissions, and FAD autofluorescence 
at 480 nm excitation and 540 nm emission.14,22,30,40 
Alternatively, other hearts were loaded with 6 μM indo 1 AM for 
30 min to measure Ca2+ transients using an excitation of 350 nm and 
emissions of 390 and 450 nm. After initially observing cytosolic Ca2+ 
transients, hearts were perfused for 15 min with 100 μM MnCl2 to 
quench the cytosolic indo 1 signal41,42 and then washed out for 15 min. 
MnCl2 slightly increased LVP which returned to its original value upon 
washout. The remaining fluorescent signal after quenching represented 
the m[Ca2+] signal.34 To estimate actual m[Ca2+] during the entire 
protocol, NADH autofluorescence was subtracted from the underlying 
changes in mCa2+ fluorescent signals for each group.14,27,43 Each signal 
was digitized and recorded at 200 Hz on computers for later analysis 
using specifically designed computational programs and commercial 
software. pH alone in the range of 6.2-8.0 does not alter the DHE 
fluorescence in our model.20 Also in preliminary experiments, we found 
that a decrease in pH from 7.4 to 6.5 did not significantly change the 
indo 1 AM fluorescence signal, and that the effects of low pH on NADH 
are negligible. This excludes the possibility of lactic acidosis buildup 
during ischemia from having significant effects on mCa2+, O2•-, and 
NADH signals during ischemia. 
Protocol 
The study had four groups: control (CON, [K+] at 4 mM, n=15); 
high [K+] cardioplegia in KR solution (CP, [K+] at 16 mM, n=21); 
lidocaine in KR solution (LID, 1 mM, n=20); and time control (n=15). 
Each group contained subsets of hearts to independently measure and 
record either NADH plus FAD, m[Ca2+], or O2•-. Each heart initially 
underwent a stabilization period followed by loading and washout of 
unbound dye to specifically measure either m[Ca2+] or O2•-. NADH and 
FAD autofluorescence were assessed simultaneously14,27,43,44 using a 
protocol similar to that of the indo 1 fluorescence dye-loaded hearts. 
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All hearts undergoing ischemia were perfused for only 1 min with 
either KR alone (CON), CP, or LID immediately before the onset of 30 
min no flow global ischemia. This protocol assured that hearts were 
treated only during the ischemic period and not during reperfusion. 
This treatment effect is not a classical preconditioning protocol in 
which a drug is first washed out before ischemia. In our protocol 
hearts began to beat immediately on reperfusion in the CP and LID 
treated hearts. This confirms that effects of CP and LID were limited to 
the 1 min perfusion and during ischemia. 
CP and LID did not alter the fluorescence characteristics or 
spectra of any dye. Therefore, any observed changes in fluorescent 
spectra were most likely attributed only to the effects induced by I/R. 
After ischemia each heart was reperfused with KR solution for 120 min 
without additional treatment. At the end of each experiment hearts 
were removed and atria were discarded; ventricles were cut into thin 
transverse sections (4-5) of approximately 3 mm each and incubated 
in buffered 0.1% 2,3,5-triphenyltetrazolium chloride (TTC) to stain 
viable tissue from necrotic tissue for estimating infarct size. 
Statistical Analysis 
Measurements for each group were compared at baseline, 
during the 1 min treatment before ischemia, at 15 and 30 min 
ischemia, and at 5, 30, 60, and 120 min reperfusion. All data are 
expressed as mean ± SEM. Values for NADH, FAD and O2•- are 
expressed in arbitrary fluorescence units (afu) with the times factors 
for photon units/s removed, and m[Ca2+] is given in nM. Between 
groups and within group comparisons were done by two-way analysis 
of variance to determine significance. If F values were significant (P < 
0.05), post hoc comparisons of means tests (Student-Newman-Keuls) 
were used to compare the three groups within each subset. 
Differences between means were considered significant when P < 0.05 
(two-tailed). 
Results 
Baseline values were not different among groups for all 
measurements. To assess the role of mitochondria in the overall 
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cardiac functional and metabolic recovery afforded by CP and LID, 
mitochondrial function, i.e., NADH plus FAD, O2•- production, and 
m[Ca2+] were monitored in different subsets of hearts undergoing the 
same protocol described earlier. Figures 1(a) and 2(a) show 
respectively timeline changes in NADH (baseline value 55±0.2 afu) 
and FAD (baseline value 61±0.7 afu) (indicators of mitochondrial 
redox state) before, during, and after ischemia. An increase in NADH 
and a decrease in FAD indicate a more reduced mitochondrial state, 
while a decrease in NADH and an increase in FAD indicate a more 
oxidized state.14,43 Ischemia initially caused an increase in NADH 
autofluorescence (afu) (62±1 afu) and a decrease in FAD (58±1 afu) 
autofluorescence in each group indicating a more reduced redox state 
during the onset of ischemia. During late ischemia mitochondria 
became less reduced as shown by the decline in NADH (56±3 afu) in 
the CON group. The CP and LID groups did not show a decline in NADH 
as did the CON group during ischemia (64±2, 65±3 afu, respectively). 
By 60 min reperfusion mitochondrial redox state (NADH and FAD) 
returned to baseline in CP and LID treated hearts (NADH: 52±1, 53±1, 
FAD: 61±1, 63±1 afu, respectively) but was markedly compromised in 
the CON group, as exemplified by the increase in FAD (67±3 afu) and 
decrease in NADH (46±1 afu) above and below baseline, respectively. 
This indicates that mitochondrial redox potential was better preserved 
with CP and LID treatment, while mitochondria exhibited a more 
oxidized state in the CON group. 
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Figure 1. (a). Change in NADH autofluorescence before, during, and after 30 min 
no flow, global ischemia for CON (n=5), CP (n=8), and LID (n=5) groups. Time control 
experiments (n=5) without concomitant ischemia are also shown. Arrow indicates 1 
min CP or LID perfusion immediately before ischemia. Figure 1(b). Effect of CP or LID 
perfusion before ischemia on NADH; white and hatched bars represent baseline and 1 
min of treatment. #P < 0.05, 1 min perfusion before ischemia, during ischemia and 
reperfusion vs. baseline values; *P < 0.05 CP or LID vs. CON; †P < 0.05 LID vs. CP 
(non significant, ns). 
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Figure 2. (a). Changes in FAD autofluorescence before, during, and after 30 min no 
flow, global ischemia for CON (n=5), CP (n=8), and LID (n=5) groups. Time control 
experiments (n=5) without concomitant ischemia are also shown. Arrow indicates 1 
min CP or LID perfusion immediately before ischemia. Figure 2(b). Effect of CP or LID 
perfusion before ischemia on FAD; white and hatched bars represent baseline and 1 
min of treatment. #P < 0.05, 1 min perfusion before ischemia, during ischemia and 
reperfusion vs. baseline values; *P < 0.05 CP or LID vs. CON; †P < 0.05 LID vs. CP 
(ns). 
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To evaluate the direct or indirect impact on mitochondrial redox 
state by CP and LID, NADH and FAD were monitored during the 1 min 
perfusion of each treatment before ischemia as shown in Figures 1(b) 
and 2(b). The baseline values were not significantly different among 
groups (average basal NADH: 55±0.2 afu) and FAD (average basal 
FAD: 61±0.7 afu). One min of CP or LID perfusion just before ischemia 
increased NADH (57.5±1.1 and 56.7±0.6 afu respectively); 1 min CP 
perfusion before ischemia slightly decreased FAD (60.1±0.4 afu); LID 
caused no change in FAD. 
Whereas NADH and FAD are markers of the mitochondrial redox 
state during I/R injury, O2•- production and m[Ca2+] are key effectors 
in the mechanism of cellular injury following I/R. Figure 3(a) shows 
that the O2•- (average baseline value 3.31±0.02 afu) level increased in 
all groups at the onset of ischemia but surged significantly higher 
during late ischemia in the CON group (4.38±0.16 afu), but not in the 
CP (3.95±0.11 afu) and LID (3.65±0.13 afu) groups. During the first 
20 min of reperfusion O2•- production returned to baseline in CP 
(3.2±0.06 afu) and LID (3.23±0.06 afu) groups, but remained 
significantly elevated in the CON group (3.57±0.14 afu). m[Ca2+] 
(average baseline value 153±3 nM) tended to increase less so during 
early and late ischemia in the LID group (344±82 nM at 30 min 
ischemia) than in the CON (569±58 nM at 30 min ischemia) and CP 
(573±119 nM at 30 min ischemia) groups (Figure 4(a)). On 
reperfusion, the high m[Ca2+] that occurred during ischemia was 
rapidly reversed toward baseline levels in both CP (213±9 nM at 5 min 
reperfusion) and LID (173±7 nM at 5 min reperfusion) groups, 
whereas it remained significantly elevated above baseline in the CON 
group throughout reperfusion (374±41 nM at 5 min reperfusion). 
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Figure 3. (a). Changes in superoxide (O2•-) levels before, during, and after 30 min 
no flow, global ischemia for CON (n=5), CP (n=6), and LID (n=6) groups. Time control 
experiments (n=5) without concomitant ischemia are also shown. Arrow indicates 1 
min CP or LID perfusion immediately before ischemia. Figure 3(b). Effect of CP or LID 
perfusion before ischemia on O2•-; white and hatched bars represent baseline and 1 
min of treatment. #P < 0.05, 1 min perfusion before ischemia, during ischemia and 
reperfusion vs. baseline values; *P < 0.05 CP or LID vs. CON; †P < 0.05 LID vs. CP 
(ns). 
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Figure 4. (a). Changes in m[Ca2+] before, during, and after 30 min no flow, global 
ischemia for CON (n=5), CP (n=6), and LID (n=7) groups. Time control experiments 
(n=5) without concomitant ischemia are also shown. Arrow indicates 1 min CP or LID 
perfusion immediately before ischemia. Figure 4(b). Effect of CP or LID perfusion 
before ischemia on m[Ca2+]; white and hatched bars represent baseline and 1 min of 
treatment. #P < 0.05, 1 min perfusion before ischemia, during ischemia and 
reperfusion vs. baseline values; *P < 0.05 CP or LID vs. CON; †P < 0.05 LID vs. CP. 
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Figures 3(b) and 4(b) summarize changes in O2•- production and 
m[Ca2+], respectively, during the one min treatment with either CP or 
LID. O2•- production decreased slightly with CP or LID treatment, 
whereas m[Ca2+] did not change. 
Ventricular infarct size as a percentage of total ventricular 
weight (area at risk) for all subgroups after 120 min reperfusion was 
significantly larger in the CON (40±2%) group than in the CP (28±3%) 
and LID (23±3%) groups. Infarcted tissue was confined principally to 
the LV mesomyocardium. 
All hearts beat spontaneously and there were no significant 
differences in heart rate among groups at baseline. Figures 6(a) and 
6(b) show timeline changes in systolic minus diastolic LVP (developed 
LVP) and diastolic LVP (diaLVP), respectively. Both treatments arrested 
all hearts during the 1 min period of perfusion with the arrest by LID 
as prompt as for CP, and on reperfusion CP and LID treated hearts 
began to beat immediately. At 5 min reperfusion developed LVP was 
higher and diaLVP was lower in CP and LID groups than in the CON 
group. By the end of reperfusion developed LVP and diaLVP in CP and 
LID groups were similar to baseline values, whereas they remained 
significantly depressed and elevated below and above baseline, 
respectively, in the CON group. CP and LID caused a small, non-
significant decrease in coronary flow (Figure 7(a)) during the 1 min 
perfusion before ischemia; during early reperfusion there was a 
reactive flow increase that was larger in the CP and LID groups than in 
the CON group. Throughout the 120 min reperfusion period coronary 
flow remained higher in the two treatment groups than in the CON 
group. Effects of both treatments and control on cardiac efficiency at 
baseline and during reperfusion are summarized (Figure 7(b)). Cardiac 
efficiency was higher after either CP or LID throughout reperfusion. 
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Figure 6. Left ventricular developed pressure (systolic–diastolic LVP (a)), and 
diastolic left ventricular pressure (diaLVP (b)) before, during, and after 30 min no flow, 
global ischemia for CON (n= 10), CP (n=15), and LID (n=14) groups. Time control 
experiments (n=10) without concomitant ischemia are also shown. Arrow indicates 1 
min CP or LID perfusion immediately before ischemia. #P < 0.05, 1 min perfusion 
before ischemia, during ischemia and reperfusion vs. baseline values; *P < 0.05 CP or 
LID vs. CON; †P < 0.05 LID vs. CP (ns). 
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Figure 7. (a). Coronary flow before, during, and after 30 min no flow, global 
ischemia for CON (n=10), CP (n=15), and LID (n=14) groups. Time control 
experiments (n=10) without concomitant ischemia are also shown. Arrow indicates 1 
min CP or LID perfusion immediately before ischemia. Figure 7(b). Effects of CP and 
LID on cardiac efficiency at selected time points during reperfusion. #P < 0.05, 1 min 
perfusion before ischemia, during ischemia and reperfusion vs. baseline values; *P < 
0.05 CP or LID vs. CON; †P < 0.05 LID vs. CP (ns). 
Cardiac contraction, cardiac relaxation, and metabolic data for 
all groups at selected times of reperfusion after ischemia were 
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compared to their respective baseline values (Table 1). Baseline values 
were similar in all groups. On reperfusion, each index was more 
improved in the two treatment groups than in the CON group, which 
was consistent with the functional data. Note that the timeline for 
mitochondrial variables and cardiac functions in the time control group 
remained unchanged during the duration of the protocol indicating 
stability of the preparation. Thus changes observed in the I/R groups 
are solely attributed to pathophysiological conditions. 
 Baseline 
Reperfusion 
5 min 
Reperfusion 
30 min 
Reperfusion 
60 min 
Reperfusion 
120 min 
O2 Delivery     
 Control 139.2±12.3 110.9±13.5# 90.8±9.2# 86.7±8.2# 94.5±8.8# 
 CP 160.9±11.2 186.1±11.6#* 131.2±10.1#* 129.8±9.4#* 136.8±8.8#* 
 LID 139.5±7.0 164.3±6.6#* 121.7±8.0* 113.7±6.4#* 128.8±5.3* 
O2 Consumption     
 Control 86.8±5.4 65.7±5.5# 58.4±5.3# 60.2±5.1# 65.4±5.0# 
 CP 105.1±4.7 101.5±8.3* 88.0±5.5#* 93.9±4.9* 99.5±5.9* 
 LID 99.8±7.4 92.5±5.9* 80.2±4.9#* 85.0±4.8#* 96.2±3.8* 
dLVP/dtmax      
 Control 1944±176 531±162# 836±134# 857±112# 882±142# 
 CP 1742±282 1123±211#* 1253±220* 1239±193* 1235±185* 
 LID 1784±106 887±178# 1298±171* 1401±108* 1360±153* 
dLVP/dtmin      
 Control -1534±143 -330±80# -660±124# -666±118# -711±131# 
 CP -1346±173 -766±144#* -1036±164* -1038±142* -1054±126* 
 LID -1458±121 -680±151#* -1130±195* -1225±147* -1171±191* 
Table 1. Changes in O2 Delivery, O2 Consumption and cardiac contractility and 
relaxation at baseline, and at selected intervals during reperfusion. Values are 
mean±sem; n=8 hearts per group 
O2 Delivery (mmHg•ml•O2•min-1•g-1); O2 Consumption (O2•g-1•min-1); Cardiac 
contractility and relaxation (mmHg/s) 
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#P < 0.05 vs. baseline values; 
*P < 0.05, each treatment vs. the control group; 
†P < 0.05, LID vs. CP. 
 
Discussion 
Cardioplegic solutions are widely used to protect hearts against 
ischemic injury during revascularization or valvular procedures while 
on cardiopulmonary bypass. These solutions have been exhaustively 
modified and reformulated in attempts to reach full cardiac recovery 
post-operatively.45 However, to achieve optimal protection it is 
important to rationally understand the mechanism by which these 
solutions provide protection against I/R injury. Insofar as mitochondria 
are implicated in I/R injury, the effects of these solutions on 
mitochondrial bioenergetics and function would provide a better 
understanding of the mechanisms of cardioprotection and the potential 
of a particular cardioprotective solution. Such studies could lead to a 
specific targeting of the mitochondrion in an attempt to improve 
clinical outcome. 
In this study we compared the impact of two preemptive 
approaches to cardiac protection on mitochondrial bioenergetics and 
global cardiac function in an isolated heart model. These were a 
plasma membrane depolarizing cardioplegia with KCl, and a 
normokalemic hyperpolarizing cardioplegia with lidocaine, both applied 
only during ischemia. To our knowledge, this is the first intact heart 
study to show and compare effects of these treatments on dynamic 
changes in mitochondrial function (NADH, FAD), O2•- generation, and 
m[Ca2+] during ischemia, and on the consequent changes in global and 
mitochondrial function during reperfusion. We found that either 
treatment, begun just before ischemia, resulted in a more normalized 
mitochondrial redox state (NADH, FAD), lower O2•- levels during I/R, 
and less mCa2+ uptake during reperfusion. This protection of 
mitochondria was associated with equivalent functional recovery of 
hearts as seen by the higher developed LVP, lower diastolic LVP, 
smaller infarct size, and higher coronary flow in the two treatment 
groups. 
Mitochondrial [Ca2+] was not significantly different between CP 
and CON throughout ischemia, even though functional recovery was 
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worst and infarct size was largest in the CON group compared to the 
treatment groups. It may be that a high m[Ca2+] during reperfusion 
rather than the mCa2+ uptake during ischemia is partially responsible 
for the damage induced by I/R. These data suggest that 
hyperpolarization with LID treatment is marginally a better approach 
than depolarization with high K+ to specifically limit mCa2+ loading 
during ischemia. 
CP and LID improve mitochondrial redox state during 
I/R 
Either NADH- or FAD-linked fluorescence can be used as a 
measure of mitochondrial redox state. Autofluorescence differences 
may reflect differences in electron flow through the electron transport 
chain (ETC).27,44,46 Ischemia caused fluorescence to increase (more 
reduced state) and FAD autofluorescence to decrease (less oxidized 
state) in all groups, which is attributed to a slower mitochondrial 
respiration because of the ischemia –induced reduction in tissue O2 
tension and O2 as an acceptor of electrons at complex IV. The redox 
state approaches the more-oxidized pre-ischemia level on reperfusion 
when the O2 tension rises.47 The marked and irreversible decline in 
NADH during late ischemia and early reperfusion in the CON group 
compared to CP and LID could be due to an increasing volume of 
irreversibly oxidized mitochondria.22 
It is possible that a decline in NADH autofluorescence during 
late ischemia was due to lactic acidosis, which may alter intracellular 
pH and consequently intra mitochondrial pH.48 However, in preliminary 
isolated heart experiments, we found negligible changes in NADH 
between pH 6.5 and 7.4. Moreover, the decline in NADH during early 
reperfusion in the CON group could be due to opening of the MPTP and 
depletion of mitochondrial NAD+49 and to greater cell death in this 
group. The decrease in redox state was associated with a larger infarct 
size in the CON group. This notion is supported by our previous study22 
showing a significant correlation between the rate of NADH decline 
throughout I/R and infarct size in individual hearts. Thus, the 
maintenance of a reduced redox state during ischemia, as shown by 
CP and LID, may be a prerequisite and a marker for the improved 
functional and metabolic recovery we observed. 
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CP and LID reduce O2•- production and mCa2+ load 
during I/R 
Both excessive mitochondrial ROS and Ca2+ are implicated in I/R 
injury. The cause-effect relationship between excess ROS and mCa2+ 
loading during I/R injury remains unsettled. We found that both CP 
and LID prevented the increase in O2•- observed in the CON group 
during late ischemia. Despite their low O2 content during ischemia, 
mitochondria are still capable of generating ROS due to the highly 
reduced redox state which promotes electron donation to residual O2 
to generate O2•-.50 It is noteworthy that NADH declined during late 
ischemia as the ROS level increased. This suggests that the increase in 
ROS production in the CON group led to mitochondrial damage and 
eventually to more cell death, and thus an irreversible decline in 
NADH. The increase in ROS generation during late ischemia in the CON 
group could result from mCa2+ overload that leads to inhibition of 
respiration;51 however, this does not explain why O2•- was lower in the 
CP group despite the higher m[Ca2+] during late ischemia. 
m[Ca2+] was lower during late ischemia in the LID group than in 
the CON group. This may be due to inhibited cell influx and/or release 
of intracellular Ca2+ by LID.52 Also LID may reduce the Na+ loading 
that occurs during ischemia and consequently reduce Na+ dependent 
Ca2+ loading.53 During late ischemia m[Ca2+] unexpectedly increased in 
the CP group to a level that was not significantly different from CON; 
but during reperfusion m[Ca2+] was significantly higher in the CON 
group than in the CP and LID treated hearts. It is unclear why CP 
treatment was associated with an increase in m[Ca2+] during ischemia. 
It could be due to intracellular Ca2+ loading as a consequence of K+-
induced membrane depolarization,54 or result from activation of 
Na+/Ca2+ exchange, or from leakage of Ca2+ from the sarcoplasmic 
reticulum during arrest.55 Regardless of the source of increased mCa2+ 
during ischemia, it appears that mCa2+ loading during ischemia may 
not be as detrimental to cardiac recovery as mCa2+ loading during 
reperfusion. This observation is consistent with another study in which 
it was shown that the most damaging Ca2+ influx occurs during 
reperfusion.56 
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Do these cardioplegic solutions directly modulate 
mitochondrial function? 
The cardioprotection afforded by CP and LID may be mediated 
through different mechanisms that directly or indirectly impact on 
mitochondrial function. Although the proposed mechanism for both CP 
and LID for protection against I/R involves their action on the 
sarcolemmal membrane to arrest the heart and reduce metabolic 
activity, there is the possibility that they also modulate mitochondrial 
function directly as a mechanism for protection of the cardiac myocyte. 
Our study shows that perfusion of hearts with CP for only 1 min before 
ischemia caused a more reduced or (less oxidized) mitochondrial state 
as evidenced by the increase in NADH and a decrease in FAD. Our 
finding of the change in redox state during 1 min of CP perfusion is 
consistent with other studies that showed an increase in NADH/NAD+ 
and FADH2/FAD ratios in hearts perfused with hyperkalemic buffer.57-59 
High K+ CP could also modulate mitochondrial function by targeting 
mitochondrial Na+/Ca2+ exchange (mNCX), and thus stimulate Ca2+ 
efflux from mitochondria where excess Ca2+ can be stored in the 
sarcoplasmic reticulum during subsequent reperfusion.60 This Ca2+ 
dynamics may account for the fast decrease in m[Ca2+] on reperfusion 
to baseline levels in the CP vs. CON groups. 
Unlike for high K+ CP, there are known direct effects of LID on 
mitochondria.61-65 The ability of a local anesthetic to penetrate the 
cellular and mitochondrial membranes depends on its lipid solubility.66 
LID can penetrate the cardiac cell membranes and be taken up by 
mitochondria.66 Moreover, low concentrations (up to 1 mM) of LID 
have been reported to stimulate mitochondrial respiration, whereas 
higher concentrations to inhibit respiration.61,65 The increase in 
mitochondrial respiration is attributed to mild uncoupling due to the 
electrophoretic entry of the cationic form of the amine.67 The inhibitory 
effect on the other hand could be ascribed to direct inhibition of the 
ETC complexes by local anesthetics.61,68 Therefore, it is possible that 
the increase in NADH we observed during the 1 min perfusion of LID 
could be due to a direct effect on mitochondrial electron transfer. In 
this way, LID could act in part like amobarbital, which blocks electron 
transfer at the rotenone site of complex I resulting in an increase in 
NADH.14 
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Interestingly, like amobarbital in our previous study, LID did not 
alter FAD, suggesting inhibition only of complex I of the ETC. This 
notion of specifically targeting mitochondrial complex I is supported by 
another study, which showed LID inhibited O2 consumption with a 
complex I substrate but not with a complex II substrate.69 However 
unlike amobarbital,14 LID treatment attenuated basal ROS generation 
(Figure 3(b)). This observation agrees with another study showing that 
LID at comparable concentrations decreased ROS generated in 
neutrophils.64 LID has also been reported to have a direct scavenging 
effect on peroxynitrite63 and on singlet oxygen.62 Therefore, the 
protective mechanisms of LID on mitochondrial function could be 
attributed to either blocking electron flow to down stream complexes 
(complex III), where greater ROS generation occurs during oxidative 
stress,14 to scavenging of mitochondrial ROS, or to both mechanisms. 
Overall it is possible that LID directly modulates mitochondrial function 
and bioenergetics to protect mitochondria against I/R injury, but its 
specific effects other than those related to Na+ channel function 
remains to be determined. 
Summary: high K+ vs. lidocaine against IR injury 
Our study demonstrates that both high K+ cardioplegia and 
lidocaine, when present during global cardiac ischemia but not 
reperfusion, help to preserve mitochondrial bioenergetics, reduce 
mCa2+ loading during reperfusion, and reduce ROS generation during 
both ischemia and reperfusion. The small but relevant changes in 
mitochondrial energetics during 1 min perfusion of either of these 
treatments before ischemia suggest that a mitochondrial related 
mechanism could be in part responsible for the cardioprotection 
conferred by these cardioplegic solutions. Although there is a definite 
advantage in the use of a high K+ cardioplegic solution for 
cardioprotection, there are some disadvantages, such as mCa2+ 
loading as shown in the present study. Moreover, it was reported that 
high [K+] can decrease cardioplegic delivery in hearts with obstructed 
coronary arteries9 due to K+ -induced coronary artery smooth muscle 
constriction,9 whereas lidocaine may improve vasodilation and lead to 
a better protection against I/R injury.70 Lidocaine may exhibit a better 
preservation of ATP compared to CP. 70 In addition to the ability of 
lidocaine to prevent arrhythmias, maintain ion homeostasis, and 
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stabilize cellular membrane potential, lidocaine may reduce the 
energy-dependent activity and thereby have energy-sparing effects.70 
Our study adds to our understanding of the mechanism of a local 
anesthetic vs a K+ cardioplegic solution for cardiac protection by 
demonstrating the important role of mitochondrial function during I/R 
injury. Although some mitochondrial differences were noted between 
these treatments, we were unable to clearly ascertain if they 
differentially underlied the improvements in cardiac function. 
 
 
Figure 5. Infarct size as a percentage of total ventricular weight measured after 
120 min reperfusion for CON (n=15), CP (n=21), and LID (n=20). *P < 0.05 CP or 
LID vs. CON; †P < 0.05 LID vs. CP (ns). 
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